Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ALVO 
Alvotech (ALVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ALVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $17.5
1 Year Target Price $17.5
| 2 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.5% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio 34.61 | 1Y Target Price 17.5 |
Price to earnings Ratio 34.61 | 1Y Target Price 17.5 | ||
Volume (30-day avg) 4 | Beta 0.1 | 52 Weeks Range 7.35 - 13.70 | Updated Date 09/17/2025 |
52 Weeks Range 7.35 - 13.70 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.23 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.26% | Operating Margin (TTM) 10.42% |
Management Effectiveness
Return on Assets (TTM) 2.83% | Return on Equity (TTM) - |
Valuation
Trailing PE 34.61 | Forward PE 15.08 | Enterprise Value 3596911185 | Price to Sales(TTM) 4.41 |
Enterprise Value 3596911185 | Price to Sales(TTM) 4.41 | ||
Enterprise Value to Revenue 6.51 | Enterprise Value to EBITDA 17.6 | Shares Outstanding 311600992 | Shares Floating 117059206 |
Shares Outstanding 311600992 | Shares Floating 117059206 | ||
Percent Insiders 61.79 | Percent Institutions 6.49 |
Upturn AI SWOT
Alvotech
Company Overview
History and Background
Alvotech is a biopharmaceutical company focused on the development and manufacturing of biosimilar medicines. Founded in 2012, it aims to improve patient access to affordable biological therapies by leveraging its fully integrated platform. Key milestones include the development of its biosimilar pipeline and regulatory approvals in various global markets.
Core Business Areas
- Biosimilar Development: Focuses on developing biosimilars of complex biologic drugs, including monoclonal antibodies and fusion proteins. The company has a pipeline of biosimilars targeting various therapeutic areas such as autoimmune diseases, oncology, and ophthalmology.
- Manufacturing: Alvotech operates a state-of-the-art manufacturing facility designed for large-scale production of biosimilars. This in-house manufacturing capability allows for greater control over product quality and supply chain.
- Commercialization Partnerships: Alvotech partners with established pharmaceutical companies to commercialize its biosimilars in different regions globally. These partnerships leverage the commercial infrastructure and market access of its partners.
Leadership and Structure
Robert Wessman is the Chairman of Alvotech. The company has a structured leadership team with expertise in biosimilar development, manufacturing, and commercialization. The organizational structure is designed to facilitate efficient decision-making and execution of its strategic objectives.
Top Products and Market Share
Key Offerings
- AVT02 (biosimilar to Humira): AVT02 is Alvotech's biosimilar to Humira (adalimumab), used to treat autoimmune diseases. While specific market share data varies by region, it competes with other adalimumab biosimilars. Competitors include Amgen (AMGN), Novartis (NVS), and other biosimilar manufacturers. While Humira has held significant market share, it has gradually decreased as biosimilars have taken some of the market share
- AVT04 (biosimilar to Stelara): AVT04 is Alvotech's biosimilar to Stelara (ustekinumab), used to treat autoimmune diseases. While specific market share data is currently unavailable as its launch is recent, it competes with other ustekinumab biosimilars. Competitors include Amgen (AMGN), Novartis (NVS), and other biosimilar manufacturers. Stelara has held significant market share.
Market Dynamics
Industry Overview
The biosimilar industry is experiencing rapid growth driven by increasing patent expirations of blockbuster biologic drugs and the demand for more affordable treatment options. Regulatory pathways for biosimilar approval are becoming more established globally, facilitating market access for biosimilar manufacturers.
Positioning
Alvotech is positioned as a key player in the biosimilar market, focusing on high-value biosimilars and leveraging its integrated platform for efficient development and manufacturing. Its competitive advantage lies in its focus on complex biologics and its strategic partnerships for global commercialization.
Total Addressable Market (TAM)
The global biosimilars market is projected to reach hundreds of billions of dollars, driven by the increasing adoption of biosimilars. Alvotech is strategically positioned to capture a significant share of this market by focusing on key therapeutic areas and expanding its global reach.
Upturn SWOT Analysis
Strengths
- Strong biosimilar development pipeline
- State-of-the-art manufacturing facility
- Strategic partnerships for global commercialization
- Focus on complex biologics
- Experienced management team
Weaknesses
- Reliance on partnerships for commercialization
- Potential for regulatory delays
- Competition from established pharmaceutical companies
- Limited operating history as a public company
Opportunities
- Expanding biosimilar market
- Increasing demand for affordable biologics
- Growing acceptance of biosimilars by healthcare providers and patients
- Entry into new markets
- Expanding the product pipeline through internal development and acquisitions
Threats
- Intense competition in the biosimilar market
- Price erosion due to biosimilar competition
- Regulatory challenges
- Intellectual property disputes
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- Amgen (AMGN)
- Viatris (VTRS)
- Novartis (NVS)
- Coherus BioSciences (CHRS)
Competitive Landscape
Alvotech competes with established pharmaceutical companies and other biosimilar manufacturers. Its advantages include its focus on complex biologics and its integrated platform. Disadvantages include its reliance on partnerships and the intense price competition in the biosimilar market.
Major Acquisitions
No acquisitions data currently available.
- Year: 2022
- Acquisition Price (USD millions): 0
- Strategic Rationale: N/A
Growth Trajectory and Initiatives
Historical Growth: Refer to Alvotech's financial reports and SEC filings to determine historical growth.
Future Projections: Analysts' estimates vary depending on market conditions and company performance. Refer to reputable financial analysis reports.
Recent Initiatives: Alvotech has been focusing on expanding its biosimilar pipeline, securing regulatory approvals for its products, and strengthening its commercial partnerships.
Summary
Alvotech, a biosimilar company, is strategically positioned to capture a sizable share of the growing market. They have strong potential to improve the access to affordable biologic therapies given their focus on complex biologics. However, Alvotech faces competition from established pharmaceutical companies. The company needs to manage regulatory hurdles and commercialize the partnered products to grow.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports and SEC filings
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alvotech
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2022-06-16 | CEO, Founder & Executive Chairman Mr. Robert Wessman | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1012 | Website https://www.alvotech.com |
Full time employees 1012 | Website https://www.alvotech.com | ||
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.